Central European Journal of Medicine

, Volume 7, Issue 5, pp 610–616 | Cite as

Evidences for oxidative stress in essential hypertension

  • Tatjana Cvetković
  • Radmila Veličković-Radovanović
  • Vidojko Djordjević
  • Sonja Radenković
  • Predrag Vlahović
  • Nikola Stefanović
Research Article



This study explores the degree of oxidative stress in essential arterial hypertension (EAH). Even oxidative stress appears as one of several metabolic abnormalities involved in essential hypertension, it remains uncertain whether is primary or secondary. However measurement of the main oxidant may be useful in order to recognize and monitor oxidative stress.


Lipid peroxidation products (TBA reac tive substances) were determined in red blood cells (RBC) and serum together with markers of antioxidant status: total antioxidative capacity (AOC), catalase activity (CAT) and RBC glutathione (GSH) content in four investigated groups. The first group consisted of regularly and adequately treated hyper tensive patients without complication (regulated), patients with hyper tension and complication of some organs and organic systems were the non-regulated group. Third group were patients at the beginning of EAH (non-treated) and controls were normotensive individuals.


Compared with controls, regulated and non-treated group, non-regulated hyper tensive pati ents had higher TBARS concen tration in plasma (p<0.001) and lower AOC, CAT activity without differences in GSH content.


Recent findings suggest that hyper tension is a condition followed by intensive oxidative stress and reduced antioxidant factors. Adequate and strictly controlled therapy, hygienic and diet regime and possible use of antioxidants can signi fi cantly reduce blood pressure and prevent possible complications.


Blood pressure Hypertension Oxidative stress 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Keaney JF, Larson MG, Vasan RS, Wilson WF, Lipinska I, Corey D, Massaro MJ, Sutherland P, Vita JA, Benjamin EJ (2003) Obesity and systemic oxidative stres. Clinical corelates of oxidative stress in the Framingham study. Hypertension 23(3): 432–449Google Scholar
  2. [2]
    Lacy F, Kailasam TM, O’Connor DT, Schmid-Schonbein GW, Parmer RJ (2000) Plasma hydrogen peroxide production in human essential hypertension. Role of heredity, gender and ethnicity. Hypertension 36(5): 878–884PubMedCrossRefGoogle Scholar
  3. [3]
    Swei A, Lacy F, DeLano FA, Schmid-Schonbein GW (1997) Oxidative stress in the DAHL hypertensive rat. Hypertension 30(6): 1628–1646PubMedCrossRefGoogle Scholar
  4. [4]
    Lacy F, O’Connor DT, Schmid-Schonbein GW (1998) Plasma hydrogen peroxide production in hyper tensives and normotensive subjects at genetic risk of hypertension. J Hypertension 16: 291–303CrossRefGoogle Scholar
  5. [5]
    Digiesi V, Lenuzza M, Digiesi G (2001) Prospects for use of antioxidant therapy in hypertension: Ann Ital Med Int 16:93–100PubMedGoogle Scholar
  6. [6]
    Dobrian AD, Schriver SD, Prewitt RL (2001) Role of Angiotensin II and free radicals in blood pre ssure regulation in rat model of renal hypertension. Hypertension 38(3): 361–376PubMedCrossRefGoogle Scholar
  7. [7]
    Dobiasova M, Frohlich J (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esteri-fication rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 34(7): 583–588PubMedCrossRefGoogle Scholar
  8. [8]
    Andreeva IL, Kožemjakin AL, Kishkun AA (1988) Modifikacija metoda opredelenia perekisej lipidov v teste s tiobarbiturovoj kislotoj. Lab Delo 11: 41–43PubMedGoogle Scholar
  9. [9]
    Jain SK, Levine NS, Duett J, Hollier B (1990) Elevated lipid peroxidation levels in red blood cells of streptozotocin-treated diabetic rats. Metabolism 39(9): 971–975PubMedCrossRefGoogle Scholar
  10. [10]
    Koraćević D, Koraćević G, ĐorĐević V, Andrejević S (1997) Simple method for the estimation of antioxidant activity in serum and other biological fluids. Balk J Clin Lab 3–4: 23–28Google Scholar
  11. [11]
    Koroljuk AM, Ivanova IL, Majorova GI, Tokarev IB (1988) Metod opredeljenja aktivnosti katalazi. Lab Delo 1: 16–18Google Scholar
  12. [12]
    Beutler E, Duron O, Kelly MB. (1963). Improved method for the determination of blood glutathione. J Lab Clin Med, 61, 882–888PubMedGoogle Scholar
  13. [13]
    García-Donaire JA, Ruilope LM (2010) Recent advances in the management of hypertension. F1000 Med Rep 2: pii: 19PubMedGoogle Scholar
  14. [14]
    Ménard J, Chatellier G (1995) Limiting factors in the control of BP: why is there a gap between theory and practice? J Hum Hypertens 2: 19–23Google Scholar
  15. [15]
    Düsing R (2006) Overcoming barriers to effective blood pressure control in patients with hyper tension. Curr Med Res Opin 8: 1545–1553CrossRefGoogle Scholar
  16. [16]
    Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ (1990) Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 86(1): 228–234PubMedCrossRefGoogle Scholar
  17. [17]
    Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23(2): 168–175.PubMedCrossRefGoogle Scholar
  18. [18]
    Papaharalambus CA, Griendling KK (2007) Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 17(2): 48–54PubMedCrossRefGoogle Scholar
  19. [19]
    Schwartz GL, Turner ST (2004) Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 4(3): 151–160PubMedCrossRefGoogle Scholar
  20. [20]
    Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, Pepine CJ, Johnson JA (2008) INVEST Investigators: beta-adrenergic receptor gene polymorphisms and betablocker treatment outcomes in hypertension. Clin Pharmacol Ther 84(6): 715–721PubMedCrossRefGoogle Scholar
  21. [21]
    Shin J, Johnson JA (2007) Pharmacogenetics of beta-blockers. Pharmacotherapy 27(6): 874–887PubMedCrossRefGoogle Scholar
  22. [22]
    Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, Liu YZ, Li Q, Zhou HH (2006) beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 80(1): 23–32PubMedCrossRefGoogle Scholar
  23. [23]
    Hadi HA, Carr CS, Al Suwaidi J (2005) Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 1(3): 183–198PubMedGoogle Scholar
  24. [24]
    Alexander WR (1995) Hypertension and the pathogenesis of atherosclerosis. Hypertension 25(2): 155–181PubMedCrossRefGoogle Scholar
  25. [25]
    Zou A-P, Li N, Cowley AW (2001) Production and actions of superoxide in the renal medulla. Hypertension 37(2): 547–565PubMedCrossRefGoogle Scholar
  26. [26]
    Wen Y, Killalea S, McGettigan P, Feely J (1996) Lipid peroxidation and antioxidant vitamin C and E in hypertensive patients. Ir J Med Sci 165(3): 210–212PubMedCrossRefGoogle Scholar
  27. [27]
    Tamer L, Sucu N, Polat G, Ercan B, Aytacoglu B, Yücebilgiç G, Unlü A, Dikmengil M, Atik U (2002) De creased serum total antioxidant status and erythrocyte-reduced glutathione levels are associated with increased serum malondialdehyde in atherosclerotic patients. Arch Med Res 33(3): 257–260PubMedCrossRefGoogle Scholar
  28. [28]
    D’souza A, Kurien BT, Rodgers R, Shenoi J, Kurono S, Matsumoto H, Hensley K, Nath SK, Scofield HR (2008) Detection of catalase as a major protein target of the lipid peroxidation product 4-HNE and the lack of its genetic association as a risk factor in SLE. BMC Medical Genetics 9: 62PubMedCrossRefGoogle Scholar
  29. [29]
    Zhou XF, Cui J, DeStefano AL, Chazaro I, Farrer LA, Manolis AJ, Gavras H, Baldwin CT (2005) Polymorphisms in the promoter region of catalase gene and essential hypertension. Dis Mar kers 21(1): 3–7Google Scholar
  30. [30]
    Nandeesha N, Sathiyapriya V, Zachariah Bobby, Pavithran P, Agrawal A, Selvaraj N. (2007). Altered oxidant-antioxidant status in non-obese men with moderate essential hypertension. Indi an J Med Sci 61(6): 326–331CrossRefGoogle Scholar
  31. [31]
    Yang H-Y, Kao P-F, Chen T-H, Tomlinson B, Ko W-C, Chan P (2007) Effects of the angiotensin ii type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients. J Clin Pharmacol 47: 397–403PubMedCrossRefGoogle Scholar
  32. [32]
    Gomes A, Costa D, Lima JL, Fernandes E (2006) Antioxidant activity of beta-blockers: an effect medi ated by scavenging reactive oxygen and nitrogen species? Bioorg Med Chem 14(13): 4568–4577PubMedCrossRefGoogle Scholar
  33. [33]
    Umemoto S, Tanaka M, Kawahara S, Kubo M, Umeji K, Hashimoto R, Matsuzaki M (2004) Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in strokeprone spontaneously hypertensive rats. Hypertens Res 27(11): 877–885PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Tatjana Cvetković
    • 1
    • 2
  • Radmila Veličković-Radovanović
    • 2
  • Vidojko Djordjević
    • 2
  • Sonja Radenković
    • 2
  • Predrag Vlahović
    • 3
  • Nikola Stefanović
    • 4
  1. 1.Institute of Biochemistry, Faculty of MedicineUniversity in NišNišSerbia
  2. 2.Departments of NephrologyClinical CenterNišSerbia
  3. 3.Departments of BiochemistryClinical CenterNišSerbia
  4. 4.Faculty of MedicineUniversity in NišNišSerbia

Personalised recommendations